4.8 Article

Registered report: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Related references

Note: Only part of the references are listed.
Article Chemistry, Medicinal

Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress

J. Jean Cui

JOURNAL OF MEDICINAL CHEMISTRY (2014)

Review Biotechnology & Applied Microbiology

The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment

Rahul A. Parikh et al.

ONCOTARGETS AND THERAPY (2014)

Meeting Abstract Oncology

Targeting HGF-mediated resistance to vemurafenib in V600E BRAF mutant melanoma cell lines

Sean Caenepeel et al.

CANCER RESEARCH (2013)

Article Pharmacology & Pharmacy

Targeting MET: why, where and how?

Elena Ghiso et al.

CURRENT OPINION IN PHARMACOLOGY (2013)

Article Oncology

HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors

Elicia Penuel et al.

MOLECULAR CANCER THERAPEUTICS (2013)

Article Multidisciplinary Sciences

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Ravid Straussman et al.

NATURE (2012)

Article Multidisciplinary Sciences

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Timothy R. Wilson et al.

NATURE (2012)

Editorial Material Oncology

Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma

Brian J. Nickoloff et al.

PIGMENT CELL & MELANOMA RESEARCH (2012)

Review Pharmacology & Pharmacy

The mesenchyme in malignancy: A partner in the initiation, progression and dissemination of cancer

Mark A. Glaire et al.

PHARMACOLOGY & THERAPEUTICS (2012)

Article Psychology, Mathematical

G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences

Franz Faul et al.

BEHAVIOR RESEARCH METHODS (2007)